Cargando…

Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report

Glioneuronal tumors are rare central nervous system tumors with heterogeneous histological and molecular features. While the majority are low grade, a small percentage can behave aggressively. Due to the rarity of these tumors, there is no consensus on how to treat high-grade glioneuronal tumors, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tadipatri, Ramya, Eschbacher, Jennifer, Fonkem, Ekokobe, Kresl, John, Azadi, Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747057/ https://www.ncbi.nlm.nih.gov/pubmed/36523718 http://dx.doi.org/10.7759/cureus.31449

Ejemplares similares

A Rare Case of Burkitt’s Lymphoma Presenting With Features Mimicking Vogt-Koyanagi-Harada Disease
por: Tadipatri, Ramya, et al.
Publicado: (2021)

The Emergence of Virtual Tumor Boards in Neuro-Oncology: Opportunities and Challenges
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

A Single-Center Experience of Dopamine Antagonist ONC201 for Recurrent Histone H3 Lysine 27-to-Methionine (H3K27M)-Mutant Glioblastoma in Adults
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

COVD-14. TELEMEDICINE REVIEW IN NEURO-ONCOLOGY: COMPARATIVE EXPERIENTIAL ANALYSIS FOR BARROW NEUROLOGICAL INSTITUTE AND GEISINGER HEALTH DURING THE 2020 COVID-19 PANDEMIC
por: Fonkem, Ekokobe, et al.
Publicado: (2020)

OTHER-03 A COMPARATIVE ANALYSIS OF BRAIN TUMOR PALLIATIVE CARE PRACTICES IN CAMEROON AND NIGERIA
por: Tadipatri, Ramya, et al.
Publicado: (2023)

Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
por: König, David, et al.
Publicado: (2022)

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
por: Frehner, Lorenz, et al.
Publicado: (2023)

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion
por: Kurozumi, Kazuhiko, et al.
Publicado: (2022)

CLRM-01 SUMMARY OF VIRTUAL TUMOR BOARD PLATFORMS AND IMPLEMENTATION IN NEURO-ONCOLOGY
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

Telemedicine review in neuro-oncology: comparative experiential analysis for Barrow Neurological Institute and Geisinger Health during the 2020 COVID-19 pandemic
por: Fonkem, Ekokobe, et al.
Publicado: (2020)

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
por: Alvarez-Breckenridge, Christopher, et al.
Publicado: (2017)

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
por: Ricciuti, Biagio, et al.
Publicado: (2019)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
Publicado: (2020)

Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
por: Hempel, Dirk, et al.
Publicado: (2020)

CLRM-02 SINGLE CENTER EXPERIENCE OF DOPAMINE ANTAGONIST ONC-201 FOR RECURRENT H3K27M-MUTANT GLIOBLASTOMA IN ADULTS
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
por: Wu, Lawrence W., et al.
Publicado: (2018)

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
por: Hemming, Matthew L., et al.
Publicado: (2020)

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal
por: Ando, Yuichi, et al.
Publicado: (2022)

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
por: Deland, Lily, et al.
Publicado: (2021)

NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
por: Wells, A.E., et al.
Publicado: (2019)

Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
por: Rosen, Ezra Y., et al.
Publicado: (2019)

Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions
por: Bogumil, Henri, et al.
Publicado: (2023)

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
por: Lin, Ruihe, et al.
Publicado: (2023)

An Exploratory Study of the Frequency of Central Nervous System Tumors by Type in the Central Texas Military and Civilian Populations
por: Murillo, Jennifer, et al.
Publicado: (2021)

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
por: Pitoia, Fabián
Publicado: (2021)

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report
por: Palmerini, Emanuela, et al.
Publicado: (2023)

Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib
por: Alharbi, Musa, et al.
Publicado: (2020)

Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report
por: Percy, Catherine, et al.
Publicado: (2021)

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
por: Zhang, Lei, et al.
Publicado: (2021)

Diffuse Leptomeningeal Glioneuronal Tumor: First Description of Metastasis to the Lung and Bone Marrow
por: Battini, Sahithi, et al.
Publicado: (2023)

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
por: Doz, François, et al.
Publicado: (2021)

Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report
por: Pircher, Magdalena, et al.
Publicado: (2021)

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
por: Waguespack, Steven G, et al.
Publicado: (2022)

Distinguishing Focal Cortical Dysplasia From Glioneuronal Tumors in Patients With Epilepsy by Machine Learning
por: Guo, Yi, et al.
Publicado: (2020)

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
por: Cervi, Catherine, et al.
Publicado: (2023)

Racial Disparities in Malignant Primary Brain Tumor Survival in Texas From 1995 to 2013
por: Ambe, Solomon, et al.
Publicado: (2020)

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
por: Ziegler, David S., et al.
Publicado: (2018)

A glioneuronal tumor with CLIP2-MET fusion
por: Chowdhury, Tamrin, et al.
Publicado: (2020)

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
por: Lu, Guangrong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5pruf312fguq47vlmfjp1o8fs5